PhRMA report shows record 313 new drugs currently in development to treat mental illness in the USA

16 July 2010

A record 313 new medicines to treat patients suffering from mental health disorders are being developed by America's pharmaceutical research and biotechnology companies, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). An estimated 300 million people worldwide ' including 60 million Americans ' struggle with mental health problems.

The report was released this week during National Minority Mental Health Awareness Month - a proclamation by the US House of Representatives in 2008 to bring attention to mental illness among minorities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >